UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Albuquerque Clinical Trials

Albuquerque Clinical Trials logo

Albuquerque Clinical Trials

Cardiovascular & MetabolicAlbuquerque, United States
Visit WebsiteContact Company

About Albuquerque Clinical Trials

Dedicated entirely to Phase II-IV clinical trials, Albuquerque Clinical Trials has operated as a locally owned, independent research centre since 1988. Based in Albuquerque, New Mexico, the site conducts studies on behalf of pharmaceutical and biotechnology sponsors across a broad range of therapeutic areas.

The facility's in-house team brings together board-certified physicians, a PharmD, certified study coordinators, licensed clinicians, regulatory specialists, recruitment professionals and data entry personnel. This integrated staffing model allows the centre to manage all phases of a trial from a single site, reducing sponsor coordination burden and supporting consistent data quality.

The active study portfolio covers a diverse set of indications, including type I and type II diabetes, obesity-related conditions, weight loss, gout, heart failure prevention, systemic lupus erythematosus, coeliac disease, migraines, male incontinence, constipation and infectious disease, including a C. difficile vaccine programme. Birth control and menstrual migraine studies are also listed among current or recent therapeutic areas, reflecting the breadth of the clinical programme.

The centre states its core commitments as exceeding sponsor expectations for dependability, human protection, subject enrolment and overall performance, with the broader aim of improving patient health through access to innovative therapies. Patient-facing infrastructure includes a dedicated sign-up pathway and a sponsor referral channel.

Further information is available at abqct.com.

Areas of Expertise

CardiovascularImmunologyInfectious DiseasePatient RecruitmentWomen's Health

Services & Capabilities

CardiovascularImmunologyInfectious DiseasePatient RecruitmentWomen's Health
Similar Companies

More in Cardiovascular & Metabolic

A

Acino

Acino operates as a speciality pharmaceutical company with a deliberate focus on emerging and underserved markets, channelling its commercial and manufacturing capabilities into regions including Africa, Latin America, the Middle East, Turkiye, North Africa, Ukraine, and the broader Eurasian corridor. This geographic strategy positions the Swiss-headquartered group where established multinationals have historically had thinner reach. The company's operational model spans three integrated pillars: partnering arrangements with third-party rights holders, in-house manufacturing supported by dedicated manufacturing sites, and direct product marketing. Quality assurance and supplier governance are identified as components of the manufacturing framework, reflecting the compliance requirements that apply across international markets. Acino's therapeutic portfolio addresses conditions prevalent in the markets it serves. Disease areas covered include cardiovascular disease, hypertension, infectious diseases, acid reflux, Helicobacter pylori infection, colorectal cancer, and narcolepsy. The company also maintains patient-facing health information on these conditions, indicating a level of engagement beyond the purely commercial. Counterfeit medicines awareness is included among its health matter communications, a consideration of particular relevance in markets with complex distribution environments. Sustainability forms part of the company's published agenda, alongside career development and media engagement, suggesting an organisation structured for long-term presence in its chosen regions rather than opportunistic market entry. Further information is available at acino.swiss.

View profile
M

Moderna

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna is a clinical-stage biotechnology company listed on the Nasdaq (ticker: MRNA) that has built its entire operation around a single scientific bet: that messenger RNA can be harnessed as a programmable medicine. Rather than developing one drug at a time, the company operates as an mRNA platform business, using the same underlying technology to generate candidates across vaccines, oncology, rare disease and cardiovascular indications. The mRNA Platform and Pipeline More than fifteen years of continuous mRNA research underpin Moderna's proprietary mRNA Design Studio, a discovery and development environment that allows scientists to design, iterate and optimise mRNA sequences with a speed that conventional small-molecule or biologics programmes cannot match. The platform has already produced two approved products: Spikevax, its COVID-19 vaccine authorised in multiple markets worldwide, and mRESVIA, an mRNA-based vaccine for respiratory syncytial virus approved by the US FDA in 2024 for adults aged 60 and over. A broad pipeline sits behind these approvals, including an investigational seasonal influenza vaccine (mRNA-1010), a personalised cancer vaccine programme developed in collaboration with Merck that uses individualised mRNA sequences to target tumour-specific neoantigens, and candidates targeting cytomegalovirus, latent HIV and rare metabolic disorders. Global Operations and Commercial Scale Moderna maintains country-specific commercial and regulatory operations across North America, Europe and Asia Pacific, with established presences in the United States, Canada, the United Kingdom, France, Germany, Italy, the Netherlands, Spain, Switzerland, Poland, Australia, Japan, South Korea, Hong Kong, Taiwan and Singapore. The company has received substantial non-dilutive funding through longstanding partnerships with US government agencies including BARDA and DARPA, which supported its early platform work. Investor relations, healthcare professional resources, supplier programmes and a clinical trials portal are all maintained as distinct operational functions, consistent with Moderna's scale as a multi-market biopharmaceutical organisation. Further information is available at modernatx.com.

View profile
4

4MCS

With a cumulative team experience of over 130 years in clinical trials and the pharmaceutical industry, 4MCS (4 Medical Clinical Solutions) operates as a patient-centred Site Management Organisation dedicated to improving the quality of research in healthcare. The organisation runs its own network of research sites and recruits volunteers from a patient population of over 10 million, giving sponsors direct access to well-characterised cohorts without the delays associated with conventional site activation. The therapeutic breadth across the site's active clinical trial programme spans respiratory conditions including asthma and COPD, cardiovascular disease areas such as atrial fibrillation and hypertension, metabolic and hepatic conditions including fatty liver disease, and a range of central nervous system and dermatological indications. Migraine, depression, general anxiety disorder, myasthenia gravis, lower back pain, psoriasis, and premenopausal effects on sexual health are among the specific areas where the organisation is actively recruiting or conducting clinical research. The patient-centred model that underpins the 4MCS approach prioritises participant experience alongside data quality, with a stated mission linked to improving patient quality of life through evidence generation. The organisation maintains dedicated disease and therapy area specialisms within its leadership and operations structure, supported by an established research site infrastructure across the United Kingdom. Further information is available at 4mcs.co.uk.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy